|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021469,
umls-concept:C0286738,
umls-concept:C0332256,
umls-concept:C0442967,
umls-concept:C0871261,
umls-concept:C1514474,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1963724,
umls-concept:C2347741,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-4-27
|
|
pubmed:abstractText |
The addition of a low dose of ritonavir to protease inhibitors (PIs) has become a widespread strategy to improve PI pharmacokinetics. As resistance is a major barrier to long-term suppression, in salvage therapy genotype and/or phenotype scoring is currently used to predict the response. We evaluated the relationship between the saquinavir (SQV) inhibitory quotient (IQ) (virtual and genotypic) and virological response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1464-2662
|
|
pubmed:author |
pubmed-author:ArnedoMM,
pubmed-author:BlancoJlJ,
pubmed-author:CarnéXX,
pubmed-author:DalmasFF,
pubmed-author:EscayolaRR,
pubmed-author:GarcíaII,
pubmed-author:GarcíaJJ,
pubmed-author:GatellJmJ,
pubmed-author:GuelarAA,
pubmed-author:JuegaJJ,
pubmed-author:López-PúaYY,
pubmed-author:LabargaPP,
pubmed-author:MallolasJJ,
pubmed-author:MartínezEE,
pubmed-author:OcampoAA,
pubmed-author:PumarolaTT,
pubmed-author:SarasaMM,
pubmed-author:TerrónAA,
pubmed-author:VergaraAA,
pubmed-author:ZárragaMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
226-33
|
|
pubmed:meshHeading |
pubmed-meshheading:17461850-Administration, Oral,
pubmed-meshheading:17461850-Adult,
pubmed-meshheading:17461850-Aged,
pubmed-meshheading:17461850-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:17461850-CD4 Lymphocyte Count,
pubmed-meshheading:17461850-Cholesterol,
pubmed-meshheading:17461850-Drug Synergism,
pubmed-meshheading:17461850-Female,
pubmed-meshheading:17461850-HIV Infections,
pubmed-meshheading:17461850-HIV Protease Inhibitors,
pubmed-meshheading:17461850-HIV-1,
pubmed-meshheading:17461850-Humans,
pubmed-meshheading:17461850-Male,
pubmed-meshheading:17461850-Middle Aged,
pubmed-meshheading:17461850-Prospective Studies,
pubmed-meshheading:17461850-Ritonavir,
pubmed-meshheading:17461850-Salvage Therapy,
pubmed-meshheading:17461850-Saquinavir,
pubmed-meshheading:17461850-Triglycerides,
pubmed-meshheading:17461850-Viral Load
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
|
|
pubmed:affiliation |
Hospital Clínic, Barcelona, Spain. mallolas@clinic.ub.es
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
